| This week's sponsor is ICON. | |  | ICON Functional Solutions
An economical delivery model that evolves with your needs with benefits beyond costs savings: - improved strategic flexibility
- innovation
- ease of management.
Read More.
|
Featured Story Monday, April 24, 2017  French biotech Genfit, a leader in the race to develop a fatty liver disease drug, said in its financials that it will delay its phase 3 NASH trial by four to six months in patients with liver scarring.
| This week's sponsor is UPS. | |  | The Temperature-Sensitive Packaging Breakdown
A survey was conducted to understand the healthcare manufacturers' efforts in developing cold-chain packaging-and the results were revealing. Take the short quiz to see how informed you are when it comes to temperature-controlled shipping. |
Top Stories Monday, April 24, 2017 Daniel Teper has stepped down immediately as CEO of New York biotech Immune Pharma as he looks to head up its new oncology spinoff. Monday, April 24, 2017 A phase 2 trial of Bristol-Myers NASH candidate BMS-986036 met its primary endpoint. The data position Bristol-Myers to talk to regulators about further development of a drug it hopes will snag a slice of the NASH market in the face of competition from Allergan, Gilead and others. Monday, April 24, 2017 Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech looks to get into the mix with its big biopharma rivals for a blockbuster market. Monday, April 24, 2017 As the saga of the EMA's location after Brexit rumbles on, European pharma leaders have drafted an open letter calling for strenuous efforts to avoid disruption at the regulator. Monday, April 24, 2017 Argenx has filed to raise up to $75 million (€69 million) in a Nasdaq IPO. The European biotech is heading across the pond in search of cash to take lead candidate ARGX-113 to the cusp of a pivotal trial while also hustling cancer candidate ARGX-110 through mid-phase studies. Monday, April 24, 2017 BD has struck a $24 billion deal to buy C.R. Bard. The takeover will strengthen BD’s position in the markets for catheters, pumps and other items while also giving it a bigger presence in fast-growing fields including oncology and biosurgery. | This week's sponsor is J.P. Morgan Private Bank. | |  | How Pre-Transaction Planning Can Maximize Your Wealth
You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article. |
| | | Private biotech HitGen has penned a new R&D collaboration with The Scripps Research Institute, as well as Calibr, that will focus on cancer, regenerative medicine and virology. Statement In its most recent late-stage trial round, known as Monarch 3, Eli Lilly says its soon-to-be-submitted CDK 4/6 breast candidate abemaciclib met its primary endpoint of showing statistically significant improvement in progression-free survival. Release As biopharmas post new data from their experimental fatty liver candidates in Amsterdam, Reuters outlines the challenges and opportunities of this future market. Reuters Health story | |
|
Resources Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
